GSK financial statements
The full income statement, balance sheet, and cash-flow statement for GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 43.1B+7.6% | 40.1B+6.3% | 37.7B+4.3% | 36.2B+6.4% | 34.0B+8.7% | |
| 31.2B+9.4% | 28.5B+5.4% | 27.1B+11.0% | 24.4B+7.2% | 22.7B+7.9% | ||
| Cost of revenue | 11.9B+3.0% | 11.6B+8.6% | 10.6B-9.6% | 11.8B+4.9% | 11.2B+10.4% | |
| Research & development | 9.93B+21.5% | 8.18B+5.7% | 7.74B+14.4% | 6.77B-2.0% | 6.90B+12.3% | |
| Operating income | 10.5B+103.8% | 5.14B-38.7% | 8.39B+5.7% | 7.93B+32.3% | 5.99B-21.9% | |
| Interest expense | 925M+8.3% | 855M-13.2% | 985M-9.1% | 1.08B+2.4% | 1.06B-5.6% | |
| Pre-tax income | 9.77B+119.9% | 4.44B-41.1% | 7.54B+8.7% | 6.94B+40.1% | 4.95B-25.3% | |
| Income tax | 1.47B+118.4% | 672M-28.5% | 940M+7.8% | 872M+663.3% | 114M+32.9% | |
| 8.30B+120.2% | 3.77B-42.9% | 6.60B-65.7% | 19.3B+174.7% | 7.01B-14.4% | ||
| Net income to common | 7.55B+129.3% | 3.29B-46.3% | 6.13B-66.8% | 18.4B+205.6% | 6.03B-18.2% | |
| $3.66+130.6% | $1.59-46.7% | $2.98-67.0% | $9.03+203.3% | $2.98-18.6% | ||
| EPS (basic) | $3.73+130.7% | $1.62-46.6% | $3.02-67.0% | $9.16+203.7% | $3.02-18.6% | |
| Weighted-avg shares (basic) | 2.03B-0.6% | 2.04B+0.6% | 2.03B+0.6% | 2.01B+0.6% | 2.00B+0.6% | |
| Weighted-avg shares (diluted) | 2.06B-0.6% | 2.07B+0.8% | 2.06B+0.7% | 2.04B+0.8% | 2.03B+0.5% | |
| Dividends per share | $1.74+11.8% | $1.56+8.1% | $1.44-4.5% | $1.51-45.1% | $2.75+7.2% | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 23.6B+10.3% | 21.4B-9.9% | 23.7B-5.2% | 25.0B-0.7% | 25.2B-7.8% | ||
| Cash & equivalents | 4.57B-6.0% | 4.87B+30.2% | 3.74B-16.7% | 4.49B-22.2% | 5.77B-32.1% | |
| Accounts receivable | 10.1B+17.0% | 8.60B-8.6% | 9.40B+10.6% | 8.50B-19.9% | 10.6B+13.1% | |
| Inventory | 7.98B+11.9% | 7.13B+1.9% | 7.00B+12.8% | 6.20B-20.5% | 7.81B-3.6% | |
| 82.3B+10.0% | 74.8B-0.5% | 75.1B+3.6% | 72.5B-32.1% | 107B-1.7% | ||
| Property, plant & equipment | 12.6B+8.1% | 11.6B+1.0% | 11.5B+6.6% | 10.8B-19.7% | 13.4B-2.4% | |
| Goodwill | 9.45B+7.6% | 8.78B+1.3% | 8.67B+2.1% | 8.49B-40.4% | 14.2B-0.4% | |
| Total non-current assets | 58.7B+9.9% | 53.4B+3.9% | 51.4B+8.3% | 47.5B-41.8% | 81.6B+0.4% | |
| 28.8B+5.5% | 27.3B+1.7% | 26.8B-2.4% | 27.5B-13.9% | 32.0B+6.9% | ||
| Short-term & current debt | 4.06B+37.3% | 2.95B-17.5% | 3.58B-24.8% | 4.76B-2.0% | 4.86B-3.3% | |
| 60.8B+4.2% | 58.3B-0.9% | 58.8B-2.5% | 60.3B-22.6% | 78.0B-3.1% | ||
| Long-term debt | 19.8B+7.6% | 18.4B-4.9% | 19.4B-5.7% | 20.5B-26.0% | 27.8B-12.2% | |
| 22.1B+28.2% | 17.2B+1.2% | 17.0B+33.0% | 12.8B-37.1% | 20.3B+3.2% | ||
| Total equity incl. non-controlling | 21.5B+30.5% | 16.5B+1.0% | 16.3B+33.9% | 12.2B-57.7% | 28.8B+2.6% | |
| Common shares issued | 2.16B+0.0% | 2.16B+0.1% | 2.16B+0.0% | 2.16B-20.0% | 2.69B+0.0% | |
| Shares outstanding (cover) | 2.16B+0.0% | 2.16B+0.1% | 2.16B+0.0% | 2.16B-20.0% | 2.69B+0.0% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 10.2B+22.0% | 8.37B-0.5% | 8.41B-7.8% | 9.13B-16.6% | 10.9B+1.0% | ||
| Depreciation & amortization | 3.05B-6.3% | 3.26B+14.3% | 2.85B+7.7% | 2.65B-9.3% | 2.92B+11.0% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt issued | 2.61B+90.2% | 1.37B+395.5% | 277M-78.1% | 1.26B | 0.00-100.0% | |
| Long-term debt repaid | 1.85B-10.4% | 2.06B-26.6% | 2.81B+43.0% | 1.97B | 0.00 | |
| Common stock issued | 19.8M-22.5% | 25.6M+105.6% | 12.4M-59.7% | 30.8M+6.7% | 28.9M-22.3% | |
| Common stock repurchased | 1.82B | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 3.38B+8.4% | 3.12B+11.8% | 2.79B-34.6% | 4.27B-22.3% | 5.50B+7.8% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 101B+44.1% | 70.0B-7.4% | 75.7B+6.3% | 71.2B-20.3% | 89.3B+20.5% | |
| P/E | 12.2×-34.5% | 18.6×+372.7% | 3.9×-61.3% | 10.2×-20.3% | 12.7×+40.8% | |
| P/S | 2.3×+34.0% | 1.7×-16.5% | 2.1×-0.1% | 2.1×-20.3% | 2.6×+10.8% | |
| P/B | 4.6×+12.4% | 4.1×-31.2% | 5.9×+69.1% | 3.5×-20.3% | 4.4×+16.8% | |
| Earnings yield | 8.2%+52.8% | 5.4%-78.8% | 25.4%+158.4% | 9.8%+25.5% | 7.8%-29.0% | |
| Dividend yield | 3.6%-22.9% | 4.6%+18.5% | 3.9%-9.5% | 4.3%-31.1% | 6.2%-10.5% | |
| Source filing | 20-F | 20-F | 20-F | 20-F | 20-F |
About this data
Source: GSK’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all GSK filings on SEC EDGAR → Not investment advice.